Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia

NCT00567671 · View on ClinicalTrials.gov ↗

Study Summary

Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.

Interventions

  • PROCEDURE Corneal collagen
  • PROCEDURE Sham comparator

Study Locations (1)

Georgia

  • Woolfson Eye Institute — Atlanta

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2007-12
Est. Completion 2010-06
Phase Phase 2

Sponsor

Emory University

1,434 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00567671

The ClinicalTrials.gov registry entry for NCT00567671 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Corneal Ectasia appearing as the primary indexed condition, and to 2 interventions — of which Corneal collagen is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00567671 reports 1 study location spanning 1 distinct geographic area — top geographies include Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00567671 about?

NCT00567671 is a clinical study titled "Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia". Prospective, randomized, single site study to determine the safety and effectiveness of performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with corneal ectasia or progressive keratoconus.

What is the current status of trial NCT00567671?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-12. Estimated completion is 2010-06.

What conditions does trial NCT00567671 study?

This clinical trial studies the following conditions: Corneal Ectasia, Progressive Keratoconus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00567671?

The interventions under investigation include: Corneal collagen (PROCEDURE), Sham comparator (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00567671?

This trial is sponsored by Emory University, which has 1,434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00567671 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial